In past studies, test subjects have been administered MT-2 once per day, while MT-1 studies have typically involved twice-daily injections
Furthermore, people with higher C-peptide levels appeared to have a somewhat lower risk of hypoglycemia

FDA-approved pharmacotherapy alternatives include several options with established safety profiles: Semaglutide (Wegovy): A GLP-1 receptor agonist producing 12-15% weight loss, with cardiovascular benefits demonstrated in the SELECT trial and FDA-approved indication for reducing cardiovascular risk Liraglutide (Saxenda): A GLP-1 receptor agonist producing 5-8% weight loss [4] Phentermine-topiramate (Qsymia): FDA-approved combination producing 7-10% weight loss with established safety data Naltrexone-bupropion (Contrave): Combination targeting reward pathways and appetite, producing 5-9% weight loss [4] Orlistat (Xenical, Alli): Lipase inhibitor producing 3-5% weight loss with gastrointestinal side effects [4] Setmelanotide (Imcivree): For rare genetic obesity disorders (POMC, PCSK1, LEPR deficiency) [4] Metabolic and bariatric surgery should be considered for patients with BMI 40 kg/m or 35 kg/m with obesity-related comorbidities who have not achieved adequate weight loss with nonsurgical interventions

Important contraindications include personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 (MEN2), history of pancreatitis, severe gastrointestinal disease including gastroparesis, and pregnancy or planned pregnancy (these medications should be discontinued at least 2 months before a planned pregnancy)